TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva is a biopharmaceutical company headquartered in Israel. It develops, manufactures and sells generic medicines, biosimilars, over-the-counter products and other medicines worldwide. Its business has three segments: United States, Europe and International Markets. Teva’s medicines include AUSTEDO for movement disorders, AJOVY for migraine prevention, UZEDY for schizophrenia and bipolar 1 disorder, and COPAXONE for relapsing forms of multiple sclerosis. Its portfolio also includes respiratory and oncology medicines. In the United States, its Anda distribution business supplies medicines to pharmacies, hospitals and physician offices. Teva also sells active pharmaceutical ingredients to third parties, provides contract manufacturing services and offers products to other pharmaceutical companies through its Medis out-licensing platform.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Teva Pharmaceuticals opposed Corcept Therapeutics' motion for summary judgment in a U.S. antitrust lawsuit. Teva claims Corcept's exclusive-dealing agreements for its Cushing's syndrome treatment, Korlym, unfairly block competition. Teva argues a jury could find these agreements substantially foreclose the market.
Teva Pharmaceuticals officers sold shares. Dov sold 26,260 shares at $41.72 each, totaling $1.1M. Sabag sold 46,000 shares at $41.93 average, totaling $1.9M. Both retain significant holdings.
Sabag Mark (See "Remarks") sold 46,000 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $41.93 ($1.93M total) on 2026-11-05.
Over the past 7 days, AlphAI's AI scored 60 news stories mentioning TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD). Coverage has skewed bullish: 39 bullish, 5 neutral, and 16 bearish.
Recent TEVA coverage spans regulation, financial news and insider activity.
In the last 30 days, TEVA insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.0M). The most active reporter was Bergwerk Dov, Interim Cheif Legal Officer, with 2 filings.
Teva's opposition may signal a prolonged litigation, potentially weighing on its stock while supporting Corcept's market position.
Insider sales may signal reduced confidence and create short-term selling pressure.
The insider sale may signal reduced confidence from an executive, creating modest downside pressure.
The insider sale may signal personal confidence concerns, potentially pressuring the stock.
The boycott could pressure Teva's revenue in the Irish and UK markets.
AlphAI scores every news story that mentions TEVA with an AI model for sentiment and relevance, and aggregates insider trades from TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Teva Pharmaceuticals opposed Corcept Therapeutics' motion for summary judgment in a U.S. antitrust lawsuit. Teva claims Corcept's exclusive-dealing agreements for its Cushing's syndrome treatment, Korlym, unfairly block competition. Teva argues a jury could find these agreements substantially foreclose the market.
Teva Pharmaceuticals officers sold shares. Dov sold 26,260 shares at $41.72 each, totaling $1.1M. Sabag sold 46,000 shares at $41.93 average, totaling $1.9M. Both retain significant holdings.
Sabag Mark (See "Remarks") sold 46,000 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $41.93 ($1.93M total) on 2026-11-05.
Bergwerk Dov (Interim Cheif Legal Officer) sold 26,260 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $41.72 ($1.10M total) across 2 trades on 2026-11-04.
The Irish Hospital Consultants Association (IHCA) urged members to avoid prescribing Teva Pharmaceuticals' products, citing ethical concerns over its ties to Israel. Teva supplies 1 in 8 prescriptions in Ireland, saving the healthcare system $1.9 billion from 2013-2018. The boycott could impact patient access to affordable medicines.
Teva Pharmaceuticals announced FDA approval of Weltruza, a once-monthly subcutaneous olanzapine injection for schizophrenia. The drug, available in three strengths, does not require post-injection monitoring. Teva expects U.S. availability soon. The SOLARIS trial showed improved symptoms and tolerability. Weltruza's list price is $3,950. (280 characters)
Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.
Teva Pharmaceuticals (TEVA) reported a 33% sales increase in its three key branded drugs, driving a revenue of $4.4B in Q3, down 2% YoY. The company's shift to higher-margin therapies improved gross profit margins to 55.5%. Teva's shares are up 34% YTD, and it recently transitioned to direct NYSE trading. The company faces challenges, including a 39% drop in U.S. generic revenues and a 47% YoY decline in EPS to $0.20 in Q3.
AstraZeneca offered $10B for Rhythm Pharmaceuticals. Boehringer Ingelheim licensed 6 cancer drugs from Sino Biopharmaceutical for $358M upfront. AbbVie licensed Nxera Pharma’s program for $100M. Lonza acquired 5 CDMO sites from Merck KGaA. Teva and Samsung Bioepis licensed 2 biosimilars. FDA approved Inovio’s Voceryq, sending shares up 257%. Agios, UniQure, NRx Pharma had FDA updates. Formation Bio raised $600M. Molecular Partners, Lenz Therapeutics, Ultragenyx announced layoffs.
Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.
